26.09.2019 2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
23.09.2019 Integration of CRISPR-cas9 technology to accelerate the discovery of innovative antibiotics DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...
18.09.2019 The efficacy of Hebelys® once again demonstrated and promoted in the International Journal of Cosmetic Science New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...
09.07.2019 Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
24.06.2019 DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...
11.06.2019 DEINOVE and AVRIL completing the development of a natural feed additive The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...
05.06.2019 DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...
21.05.2019 Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...
20.05.2019 The US Department of Defense and Deinove will present impactful R&D results during the coming ASM 2019 The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...
16.05.2019 DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...